2QFO

HSP90 complexed with A143571 and A516383


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.68 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.224 
  • R-Value Observed: 0.246 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.

Huth, J.R.Park, C.Petros, A.M.Kunzer, A.R.Wendt, M.D.Wang, X.Lynch, C.L.Mack, J.C.Swift, K.M.Judge, R.A.Chen, J.Richardson, P.L.Jin, S.Tahir, S.K.Matayoshi, E.D.Dorwin, S.A.Ladror, U.S.Severin, J.M.Walter, K.A.Bartley, D.M.Fesik, S.W.Elmore, S.W.Hajduk, P.J.

(2007) Chem Biol Drug Des 70: 1-12

  • DOI: 10.1111/j.1747-0285.2007.00535.x
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • The molecular chaperone HSP90 has been shown to facilitate cancer cell survival by stabilizing key proteins responsible for a malignant phenotype. We report here the results of parallel fragment-based drug design approaches in the design of novel HSP ...

    The molecular chaperone HSP90 has been shown to facilitate cancer cell survival by stabilizing key proteins responsible for a malignant phenotype. We report here the results of parallel fragment-based drug design approaches in the design of novel HSP90 inhibitors. Initial aminopyrimidine leads were elaborated using high-throughput organic synthesis to yield nanomolar inhibitors of the enzyme. Second site leads were also identified which bound to HSP90 in two distinct conformations, an 'open' and 'closed' form. Intriguingly, linked fragment approaches targeting both of these conformations were successful in producing novel, micromolar inhibitors. Overall, this study shows that, with only a few fragment hits, multiple lead series can be generated for HSP90 due to the inherent flexibility of the active site. Thus, ample opportunities exist to use these lead series in the development of clinically useful HSP90 inhibitors for the treatment of cancers.


    Organizational Affiliation

    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Heat shock protein HSP 90-alphaA, B207Homo sapiensMutation(s): 0 
Gene Names: HSP90AA1HSP90AHSPC1HSPCA
Find proteins for P07900 (Homo sapiens)
Explore P07900 
Go to UniProtKB:  P07900
NIH Common Fund Data Resources
PHAROS  P07900
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
A51
Query on A51

Download CCD File 
A
(3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
C11 H11 N O2
BKXNPYSVWOVZGX-CMDGGOBGSA-N
 Ligand Interaction
A13
Query on A13

Download CCD File 
A
4-METHYL-6-(TRIFLUOROMETHYL)PYRIMIDIN-2-AMINE
C6 H6 F3 N3
CNTCLEOUAMWZGS-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
A13Kd:  20000   nM  BindingDB
A51Kd:  150000   nM  Binding MOAD
A13Kd :  20000   nM  PDBBind
A13Kd:  20000   nM  BindingDB
A13Ki:  18000   nM  Binding MOAD
A13Ki:  18000   nM  BindingDB
A13IC50:  18270   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.68 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.224 
  • R-Value Observed: 0.246 
  • Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 64.157α = 90
b = 88.755β = 90
c = 98.445γ = 90
Software Package:
Software NamePurpose
CNXrefinement
HKL-2000data collection
HKL-2000data reduction
HKL-2000data scaling
CNSphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2007-06-27 
  • Released Date: 2008-07-01 
  • Deposition Author(s): Park, C.H.

Revision History 

  • Version 1.0: 2008-07-01
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2014-04-16
    Changes: Refinement description